-transparent.png){kind=logo}
Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic use of FVIII in children and adults with severe hemophilia A, and 4) affordability and availability of FVIII products. Improving patient outcomes by increasing the use of FVIII prophylaxis, preventing or eliminating FVIII inhibitors, and expanding access to FVIII concentrates in developing countries are the major challenges confronting clinicians who care for patients with hemophilia A.
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
January 1991,
Annals of the New York Academy of Sciences,
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
October 2017,
Therapeutic advances in hematology,
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
December 2011,
Journal of genetic syndromes & gene therapy,
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
April 2009,
Therapeutics and clinical risk management,
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
April 1972,
The American journal of the medical sciences,
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
July 2016,
Expert review of hematology,
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
March 2009,
Molecular therapy : the journal of the American Society of Gene Therapy,
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
September 2020,
The New England journal of medicine,
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
August 1986,
Annals of internal medicine,
Louis Aledort, and
Rolf Ljung, and
Kenneth Mann, and
Steven Pipe
October 2000,
Haematologica,
